# Hemant Surgical Industries share price today (Hemant Surgical Industries Ltd, BSE: 543916)

> Hemant Surgical Industries share price today: ₹597.35 at the BSE close on 3 November 2026. Hemant Surgical Industries (BSE: 543916) is worth ₹868 crore and trades at a P/E of 51.2. > Hemant Surgical Industries Ltd's results are improving, and its P/E is near the top of its own history, higher than 97% of past readings. 543916 · Medical Equipment · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/hemant-surgical-industries-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹597.35
- P/E: 51.2× (higher than 97% of the last 3.4 years)
- Revenue (Mar 2026): ₹167 Cr (+187.9% on a year ago)
- Profit (Mar 2026): ₹13.0 Cr (+160.0% on a year ago)
- Operating margin: 9.0% (−1.0 points on a year ago)
- ROCE: 19%, FY26
- ROIC: 12.7%, against a 12.0% cost of capital: +0.7 points
- Profit that came in as cash: −86%, last 3 years

The main question: profits are rising, but only −86% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Hemant Surgical Industries share price today? Hemant Surgical Industries Ltd's share price was ₹597.35 at the close on 3 November 2026. It has been rising for 66 weeks. That is 49.6% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 10 weeks in a row. Since its first close in our records, on 27 March 2026, it has traded between ₹243 and ₹666, and at that close it sat 84% of the way up from that low. Over the last 7 months the share price moved +146% while the NIFTY 500 moved +5%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Hemant Surgical Industries this quarter? Three changes stood out: number of shareholders up 59% in a year, highest quarterly profit in 8 quarters and highest quarterly revenue in 8 quarters. 1. Number of shareholders up 59% in a year 1,202 shareholders in the September 2026 quarter, against 758 a year earlier. 2. Highest quarterly profit in 8 quarters Profit of ₹13 crore in the March 2026 quarter is the highest of the last 8 quarters. 3. Highest quarterly revenue in 8 quarters Revenue of ₹167 crore in the March 2026 quarter is the highest of the last 8 quarters. ## What are Hemant Surgical Industries' latest quarterly results? For January to March 2026 (the quarter ended 31 March 2026), Hemant Surgical Industries reported revenue of ₹167 crore, up 187.9% from ₹58.0 crore a year earlier, and a profit of ₹13.0 crore, up 160.0% from ₹5.00 crore. ### Hemant Surgical Industries results: January to March 2026 against a year earlier

| Measure | January to March 2026 | January to March 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹167 crore | ₹58.0 crore | +187.9% |
| Profit | ₹13.0 crore | ₹5.00 crore | +160.0% |
| Earnings per share | ₹9.84 | ₹4.74 | +107.6% |
| Operating margin | 9.0% | 10.0% | −1.0 points |

The next results, for April to June 2026, were due by 14 August 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). This page shows them once our weekly data update has read them. (From the company's reported quarterly results (quarter ended 31 March 2026). Revenue and profit in ₹ crore.)

## What is the Hemant Surgical Industries share price history? Hemant Surgical Industries closed at ₹597.35 on 3 November 2026. Its highest weekly close since March 2026 was ₹665.60 on 9 October 2026. ### Hemant Surgical Industries share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹570.00 | +4.8% |
| 1 month ago · 1 Oct 2026 | ₹610.50 | −2.2% |
| 6 months ago · 30 Apr 2026 | ₹301.20 | +98.3% |
| Earliest and lowest weekly close in our records · 27 Mar 2026 | ₹242.95 | +145.9% |
| Highest weekly close since March 2026 · 9 Oct 2026 | ₹665.60 | −10.3% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (37 weekly closes from 27 March 2026 to 3 November 2026.)

## What is the latest news on Hemant Surgical Industries? 3 Nov 2026: Hemant Surgical Industries closed at ₹597.35, up 4.8% on the week and down 2.2% on the month. Results for January to March 2026: Revenue up 187.9% and profit up 160.0% on a year earlier. ## What dividend does Hemant Surgical Industries pay? No. Hemant Surgical Industries Ltd paid out 0% of its profit as dividends in each of its last 9 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate (as of 3 November 2026). ## Which stock lists is Hemant Surgical Industries on? Hemant Surgical Industries is on one of our India lists: Momentum stocks. [Momentum stocks Market cap cr: 850.1391213389121](https://www.sectoralpha.in/momentum-stocks-india)

## Is Hemant Surgical Industries profitable? Hemant Surgical Industries Ltd earned ₹13.0 Cr of net profit in the Mar 2026 quarter, +160.0% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹18.0 Cr. Over 8 years profit has grown 43.5% a year on average. That is 7.8% of the quarter's revenue. The same quarter a year earlier earned ₹6.0 Cr. For the full year, FY26 profit was ₹18.0 Cr (+125.0% on the year before). Why profit moved: revenue changed +187.9% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +46.3% and revenue +55.2%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Hemant Surgical Industries make, and is it growing? Hemant Surgical Industries Ltd reported ₹167 Cr of revenue in the Mar 2026 quarter, +187.9% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 8 years it has grown 20.8% a year on average. The last full year, FY26, came in at ₹231 Cr. FY26 revenue was ₹231 Cr, +115.9% on the year before. Recent pace: the last four quarters grew +55.2% on average, against 20.8% a year over the longer run, so this year is growing faster than its own long-run rate. ## How much of every ₹100 of sales does Hemant Surgical Industries keep? Hemant Surgical Industries Ltd's operating margin was 9.0% in the Mar 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Over the last four quarters it has moved −4.0 percentage points. Across 9 years it has been between 4.7% and 10.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −3.2 percentage points on the year while gross margin changed −7.9 points. So the drop came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Hemant Surgical Industries' profit turning into cash? Over the last 3 years Hemant Surgical Industries Ltd's operations used more cash than they brought in, so cash conversion was −86%, a gap worth watching. In FY26 its operations used ₹32.0 Cr of cash, against ₹18.0 Cr of profit. After ₹3.0 Cr of spending on assets, free cash was −₹35.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why −86% of profit came in as cash: the cash cycle got 29 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 29 days longer. The next section looks at where the cash is stuck. ## Where does Hemant Surgical Industries' cash go? Hemant Surgical Industries Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 80 days in FY26, up from 51 days in FY21. It spent ₹44.0 Cr on assets over the last 3 years. Customers take 106 days to pay, and stock sits for 120 days on average. At FY26 sales of ₹231 Cr, each day of that cycle ties up about ₹0.6 Cr, so roughly ₹51.0 Cr is tied up in the business at any time. FY26: customers took 106 days to pay and stock sat for 120 days, about 3.9 months of sales sitting as stock, for a full cycle of 80 days, longer than FY21's 51. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 120 days. Customers pay about 106 days after that. Suppliers are paid at 146 days. Together that makes the 80-day cycle. Spending on assets: ₹44.0 Cr over the last 3 years, against ₹4.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Hemant Surgical Industries' P/E ratio, and how does it compare with its own history? Hemant Surgical Industries Ltd's P/E is 51.2×, near the high end of its own history: higher than 97% of past readings. Its usual P/E (the middle reading) is 25.8×, over 3.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Hemant Surgical Industries business getting better or worse? Hemant Surgical Industries Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Hemant Surgical Industries earn on its capital? Hemant Surgical Industries Ltd earned a ROCE of 19% in FY26. That is up from a low of 12% in FY20. Its return on capital used (ROIC) is 0.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 7.8% net margin and 0.84× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 7.8% net margin × 0.84× asset turnover × 2.00× leverage (assets divided by equity) ≈ 13.1% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 12.7% − 12.0% = +0.7 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. ## Does Hemant Surgical Industries have too much debt? Hemant Surgical Industries Ltd had ₹50.0 Cr of borrowings against ₹137 Cr of equity in FY26, so its debt is 0.36× its equity. Its operating profit is 6 times its interest bill. Over 5 years borrowings went from ₹14.0 Cr to ₹50.0 Cr. Over the last 3 of those years it spent ₹44.0 Cr on assets. Part of the spending on assets is being paid for with borrowed money. ## What is the Hemant Surgical Industries shareholding pattern? Promoters cut their stake in Hemant Surgical Industries Ltd by 20.7 percentage points over 7 quarters, the biggest change among its owners. Promoters now own 52.8% of the company. Domestic institutions moved +15.7 points over the same period, to 19.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −20.7 points over 7 quarters, to 52.8%; Domestic institutions: +15.7 points over 7 quarters, to 19.9%; Foreign institutions: +0.0 points over 7 quarters, to 0.0%. Why the owners changed: promoters drove it (−20.7 points), with the other side taken by domestic institutions (+15.7 points). They reduced their stake. ## How far is Hemant Surgical Industries from balance-sheet trouble? For Hemant Surgical Industries Ltd, the Z-score is 2.87. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.87 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Hemant Surgical Industries rank in its industry? 60.8 out of 100, rank 6 of 6 in Medical Equipment, with 48% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Hemant Surgical Industries Ltd scores 60.8 out of 100 against the 6 companies it is compared with in Medical Equipment, ranking 6. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 23 + 15.6 + 9.7 + 12.5 = 60.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Hemant Surgical Industries compared with? Hemant Surgical Industries ranks 6 of 6 Medical Equipment companies on the 4-Factor Sector Score, with 60.8 out of 100. 1. [Laxmi Dental Ltd](https://www.sectoralpha.in/stocks/laxmi-dental-ltd) LAXMIDENTL · quiet · Evidence leans up · 68% evidence 53.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 16.7% · Profit 34.8% · Operating margin change 1 points · 100% evidence Capital efficiency 14.5/25 · ROCE 15% · Operating margin 19% · 100% evidence Valuation 10.9/20 · P/E 28.1× · PEG n/a · 15% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -13.9% · 1 year -43.5% · 25% evidence · 0 of 12 weeks ahead Exact sum: 20.4 + 14.5 + 10.9 + 7.5 = 53.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Vasa Denticity Ltd](https://www.sectoralpha.in/stocks/vasa-denticity-ltd) DENTALKART · breaking out · Evidence leans down · 75% evidence 35.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.3/35 · Revenue 17.9% · Profit -30.2% · Operating margin change 1.1 points · 100% evidence Capital efficiency 4.6/25 · ROCE 7% · Operating margin 6.1% · 100% evidence Valuation 6.9/20 · P/E 65× · PEG n/a · 50% evidence Relative strength 9.9/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.8% · 1 year -27.7% · 25% evidence · 8 of 12 weeks ahead Exact sum: 14.3 + 4.6 + 6.9 + 9.9 = 35.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Poly Medicure Ltd](https://www.sectoralpha.in/stocks/poly-medicure-ltd) POLYMED · quiet · Most evidence points down · 100% evidence 31.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.5/35 · Revenue 18.4% · Profit -12.3% · Operating margin change -2 points · 100% evidence Capital efficiency 13.3/25 · ROCE 12.5% · Operating margin 24% · 100% evidence Valuation 5.2/20 · P/E 45.9× · PEG 3.87 · 100% evidence Relative strength 0.9/20 · Lead over its industry -19.9% · Lead over NIFTY 500 -4.6% · 1 year -27.5% · 100% evidence · 6 of 12 weeks ahead Exact sum: 12.5 + 13.3 + 5.2 + 0.9 = 31.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Tarsons Products Ltd](https://www.sectoralpha.in/stocks/tarsons-products-ltd) TARSONS · losing its lead · Most evidence points down · 75% evidence 29.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 5.8/35 · Revenue 10.6% · Profit -59.7% · Operating margin change -3.5 points · 100% evidence Capital efficiency 6.6/25 · ROCE 4.6% · Operating margin 23.6% · 100% evidence Valuation 5.4/20 · P/E 131× · PEG n/a · 50% evidence Relative strength 11.7/20 · Lead over its industry n/a · Lead over NIFTY 500 22.2% · 1 year 0.7% · 25% evidence · 10 of 12 weeks ahead Exact sum: 5.8 + 6.6 + 5.4 + 11.7 = 29.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Prevest Denpro Ltd](https://www.sectoralpha.in/stocks/prevest-denpro-ltd) PREVEST · Too little evidence to rank firmly · 43% evidence 64.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.5/43.75 · Revenue 17.3% · Profit 17% · Operating margin change -0.6 points · 53% evidence Capital efficiency 23.6/31.25 · ROCE 25.2% · Operating margin 33.9% · 57% evidence Valuation 17.3/25 · P/E 24.8× · PEG n/a · 50% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 23.5 + 23.6 + 17.3 = 64.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 6. Hemant Surgical Industries Ltd this page breaking out · Too little evidence to rank firmly · 48% evidence 60.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.0/35 · Revenue 57.2% · Profit 52.9% · Operating margin change -1 points · 48% evidence Capital efficiency 15.6/25 · ROCE 18.9% · Operating margin 9% · 95% evidence Valuation 9.7/20 · P/E 49.2× · PEG n/a · 15% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 67.5% · 1 year n/a · 25% evidence · 8 of 12 weeks ahead Exact sum: 23 + 15.6 + 9.7 + 12.5 = 60.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Equipment](https://www.sectoralpha.in/sectors/medical-equipment), all 6 compared on one page. ## Which companies are close to Hemant Surgical Industries in size? Hemant Surgical Industries is the 4th largest of 6 Medical Equipment companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Poly Medicure, Tarsons Products and Laxmi Dental. Just below it: Vasa Denticity and Prevest Denpro. ### Medical Equipment companies close in size

1. [Poly Medicure Ltd](https://www.sectoralpha.in/stocks/poly-medicure-ltd) ₹14,692 crore
2. [Tarsons Products Ltd](https://www.sectoralpha.in/stocks/tarsons-products-ltd) ₹1,548 crore
3. [Laxmi Dental Ltd](https://www.sectoralpha.in/stocks/laxmi-dental-ltd) ₹977 crore
4. Hemant Surgical Industries Ltd ₹834 crore
5. [Vasa Denticity Ltd](https://www.sectoralpha.in/stocks/vasa-denticity-ltd) ₹754 crore
6. [Prevest Denpro Ltd](https://www.sectoralpha.in/stocks/prevest-denpro-ltd) ₹510 crore

[All 6 Medical Equipment companies, largest first](https://www.sectoralpha.in/sectors/medical-equipment#all-companies)

### Companies close in size in other industries

1. [Quick Heal Technologies Ltd](https://www.sectoralpha.in/stocks/quick-heal-technologies-ltd) ₹838 crore · IT - Software
2. [Jindal Supreme (India) Ltd](https://www.sectoralpha.in/stocks/jindal-supreme-indialtd) ₹836 crore
3. Hemant Surgical Industries Ltd ₹834 crore
4. [Sree Rayalaseema Hi-Strength Hypo Ltd](https://www.sectoralpha.in/stocks/sree-rayalaseema-hi-strength-hypo-ltd) ₹833 crore · Chemicals - Inorganic
5. [Madras Fertilizers Ltd](https://www.sectoralpha.in/stocks/madras-fertilizers-ltd) ₹832 crore · Fertilisers

## What else do people ask about Hemant Surgical Industries? ### What is Hemant Surgical Industries's share price today? Hemant Surgical Industries Ltd's share price is ₹597.35. The whole company is worth ₹868 Cr on the market. In the last 52 weeks it traded between ₹243 to ₹666; today it is 84% of the way up from the low, 49.6% above its 200-day average. The price has been rising for 66 weeks (as of 3 November 2026). ### What were Hemant Surgical Industries's latest quarterly results? Hemant Surgical Industries Ltd reported revenue of ₹167 Cr and net profit of ₹13.0 Cr for the Mar 2026 quarter. Revenue rose 187.9% and profit rose 160.0% compared with a year earlier. Earnings per share were ₹9.84. The operating margin was 9.0%, 1.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Hemant Surgical Industries's market cap? Hemant Surgical Industries Ltd's market capitalisation is ₹868 Cr at a share price of ₹597.35. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Hemant Surgical Industries performing? Hemant Surgical Industries Ltd's share price has been rising for 66 weeks. In its latest quarter, revenue rose 187.9% and profit rose 160.0% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 10 weeks running (as of 3 November 2026). ### Is Hemant Surgical Industries in an uptrend? Yes, the price has been rising for 66 weeks (stage 2 of 4), 49.6% above its 200-day average, and 84% of the way up its 52-week range. A share price tends to move through four phases: moving sideways, rising, stalling and falling (as of 3 November 2026). ### Will Hemant Surgical Industries's share price go up? This page does not forecast Hemant Surgical Industries Ltd's share price. What it shows instead: the share price is ₹597.35, and it has been rising for 66 weeks. Its P/E of 51.2× is higher than 97% of its own last 3 years (as of 3 November 2026). ### Who owns Hemant Surgical Industries? Promoters own 52.8% of Hemant Surgical Industries Ltd, foreign institutions 0.0%, domestic institutions 19.9% and the public 27.2% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 20.7 percentage points over 7 quarters (as of 3 November 2026). ### Where is Hemant Surgical Industries in its business cycle? Hemant Surgical Industries Ltd's FY26 operating margin was 10.0%, against a 9-year range of 4.7% to 10.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 9.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Hemant Surgical Industries story? The main question: profits are rising, but only −86% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Hemant Surgical Industries a stock worth studying right now? What the numbers show: Hemant Surgical Industries Ltd's results are improving, and its P/E is near the top of its own history, higher than 97% of past readings. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india

This is research, not advice. We’re not SEBI-registered.